IL33 and Cognitive impairment: Intraperitoneal injections (50 mg/kg, about 1.15 mg per animal, 10 days) followed by intrahippocampal injection (400 ng by side) of IL-33 in 8-week-old mice, evoked neuroinflammation and cognitive impairment [170], whereas intraperitoneal injections (200 ng, 7 days) of IL-33 in transgenic mouse models of AD (mice, 48 weeks old) mobilized microglia to prevent and clear Aβ-deposits, thus ameliorating cognitive impairment [171].